Drug
Gwp42003 P KG Day Dose
Gwp42003 P KG Day Dose: highest development phase Phase 3, developed by Jazz Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| GWP42003-P 20 mg/kg/day Dose NCT02224690 | Phase 3 | Epilepsy |
Latest
No recent events.
Follow Gwp42003 P KG Day Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.